House debates Bills

Health Legislation Amendment (Improved Medicare Integrity and Other Measures) Bill 2024; Second Reading

Thursday, 28 November 2024 House of Representatives

Ged Kearney

Ged Kearney Cooper, Australian Labor Party, Assistant Minister for Health and Aged Care

6:15 pm

I move:

That this bill be now read a second time.

Today, I introduce the Health Legislation Amendment (Improved Medicare Integrity and Other Measures) Bill 2024.

Australia has a world-class health system that offers affordable, high-quality, accessible health care to all Australians. This is due in large part to the various health benefit schemes—including Medicare and its programs—that help Australians pay for the health care they need.

The government is committed to protecting and strengthening Medicare—and part of this is improving the compliance framework that ensures the integrity of these rebates.

The Independent Review of Medicare Integrity and Compliance undertaken by Dr Pradeep Philip, known as the Philip review, was commissioned by the government to respond to concerns about the operation of the Medicare system.

In 2023, the Health Insurance Amendment (Professional Services Review Scheme) Act 2023 and the Health Insurance Amendment (Professional Services Review Scheme No. 2) Act 2023 made priority amendments in response to this review.

Now that these urgent amendments have been made, this bill implements additional proposals to respond to Philip review recommendations including reducing the timeframe for making bulk-billed claims to support the integrity and ongoing sustainability of Medicare.

The bill implements a measure announced in the 2024-25 budget: reducing the timeframe during which Medicare claims for bulk-billed services can be made from two years to one year. Claims relating to bulk-billed services can currently be made up to two years after a health service has been provided. The bill will improve payment integrity and reduce the number of incorrect and fraudulently submitted claims. This is likely to have minimal impact on patients and practitioners as most claims are already made within 12 months. There will be discretion to accept claims after that time to ensure patients are not disadvantaged.

Investigative powers

Currently, a range of legislative provisions across health portfolio legislation are creating barriers to effective compliance activities, particularly when it comes to deterring and responding to serious non-compliance and fraud.

The bill responds to these barriers by allowing investigative powers to be used consistently and effectively across Medicare and the Pharmaceutical Benefits Scheme. Changes will also enable powers to be used in the investigation of Criminal Code offences and remove the need for AFP assistance with executing warrants for suspected Criminal Code offences.

These amendments will improve investigative powers in health portfolio legislation and ensure they can be put into practice consistently, effectively and proportionately to respond to behaviour that jeopardises the integrity of health benefits schemes.

Pharmacy approval process

Under the National Health Act 1953, a pharmacist can request that the Minister for Health and Aged Care exercise a discretion to approve the supply of pharmaceutical benefits at particular premises. This is currently a two-stage process, which can take up to six months. This is frustrating and time-consuming for the applicant and may also delay the community's access to pharmaceutical benefits.

In this bill, the two-stage process is proposed to be streamlined and condensed into a single-stage process of up to four months. This will help to reduce a significant administrative burden. And it will provide the community with more timely access to pharmaceutical benefits in appropriate cases.

The bill makes several sensible amendments to the Therapeutic Goods Act 1989(the Therapeutic Goods Act) to:

      The bill enhances the capacity of the government to manage and alleviate the consequences of therapeutic goods shortages in Australia.

      This measure expands an existing mechanism in the Therapeutic Goods Act to help deal with critical shortages of medicines, biologicals and medical devices that are approved for supply in Australia, by allowing the secretary of the department to approve the importation or supply of substitutable unapproved products from overseas if the Secretary is satisfied that the approved medicine, biological or medical device may, in the reasonably foreseeable future, become unavailable or be in short supply.

      Before exercising this power, the secretary would consider the suitability of granting such an approval, including whether it is in the interest of public health. This is necessary because the Therapeutic Goods Act currently only allows the Secretary to exercise this power when satisfied that approved medicines, biologicals or medical devices are already unavailable or in short supply. The limitation hinders Australia's present capacity to act nimbly in this area.

      The bill supports compliance and enforcement activities in relation to both unlawful therapeutic goods and unlawful vaping goods.

      Specifically, the bill broadens the circumstances in which section 52AAA applies to ensure that forfeiture arrangements can extend to the range of circumstances in which goods may be seized under the Therapeutic Goods Act. Rather than, as currently, only the circumstance where goods are seized under a warrant issued under section 50. This amendment will help deter the trafficking of such goods by sending a strong message to bad actors operating in this space that the Therapeutic Goods Administration (the TGA) will take unlawful goods permanently.

      The bill also ensures the relevant parts of the Act are better aligned with the model provisions of the Regulatory Powers (Standard Provisions) Act 2014 in relation to the powers and functions of persons assisting an authorised person executing a warrant and provides investigators greater flexibility when temporarily ceasing the execution of a warrant.

      The bill lowers the threshold that must be satisfied before the secretary may give an enforceable direction to a person under section 42YT of the Therapeutic Goods Act. The current requirement is that a direction is necessary to protect the health and safety of humans. The amendment will result in a more balanced approach that a direction must be considered and issued in the interests of public health and safety. This approach ensures the more appropriate availability of such directions to protect Australians from new and emerging public health threats.

      The bill enhances the ability of state and territory officers to monitor, investigate and enforce compliance with the Therapeutic Goods Act and Regulations by allowing for the provision, inspection, copying and retention of documents or information.

      The bill also clarifies that section 61, which authorises the release of information in relation to therapeutic goods and vaping goods in certain circumstances, is not a secrecy provision.

      Other amendments to the Therapeutic Goods Act

      The bill includes other amendments to the Therapeutic Goods Act, principally to:

                    The bill also amends the Therapeutic Goods Act to make minor consequential amendments to support the government's ground-breaking vaping reforms.

                    The bill makes minor refinements to:

                          The bill also clarifies that the authority for making determinations to cease supply of vaping goods resides in the regulations, rather than the act. This enables the secretary to make a single decision in relation to a vaping good which is rightly the subject of merits review.

                          In addition, the bill makes minor amendments to:

                              Consistent with this government's unwavering commitment to public health, these measures support strong and effective regulation under the Therapeutic Goods Act.

                              Finally, the bill amends the Public Health (Tobacco and Other Products) Act 2023(the tobacco act) which commenced on 1 April 2024. These amendments clarify the intended operation of the provisions and are amendments that have been identified as necessary in the implementation phase of the legislation.

                              The amendments remove the restriction on which Australian Public Service employees can be 'authorised officers' for the purpose of tobacco enforcement and compliance. This will mean that the compliance team for the tobacco act can be drawn from any portfolio within the APS, consistent with past practice. In the past National Measurement Institute officers from the Department of Industry, Science and Resources have performed this important role.

                              The amendments provide for phase-in and phase-out provisions to be included in regulations when details included in the regulations are updated in future. The intention is that health warnings, health promotion inserts and images displayed on tobacco products and packaging are refreshed. This is directed to maximising their effectiveness to deter uptake and encourage cessation of smoking. Phase-in and phase-out provisions will ensure that regulations provide for time periods for industry preparation and for retailers to sell through stock.

                              The amendments also clarify the interaction between the Therapeutic Goods Act and the tobacco act advertising provisions relating to e-cigarettes (also known as vapes). Both acts prohibit the advertisement of vapes. These amendments reflect the changed approach to vaping goods following the introduction of the vaping reforms to ensure the approach is harmonised.

                              The measures in this bill will further the government's efforts to strengthen Medicare and will assist in the implementation of our world-leading tobacco and vaping reforms.

                              I commend the bill to the House.

                              Debate adjourned.

Comments

No comments